Osteoporosis outcome evaluation

Badia X, Diez-Perez A, Lahoz R, Lizan L, Nogues X, Iborra J (2004) The ECOS-16 questionnaire for the evaluation of health related quality of life in post-menopausal women with osteoporosis. Health Qual Life Outcomes 2(1) 41... 

Delmas PD, Ensrud KE, Adachi JD, Harper KD, Sarkar S, Gennari C, Reginster JY, Pols HAP, Recker RR, Harris ST, Wu W, Genant HK, Black DM, Eastell R for the Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators (2002) Efficacy of raloxifene on vertebral fracture risk reduction in postmenopausal women with osteoporosis four-year results from a randomized clinical trial. J Clin Endocrinol Metab 87 3609-3617... 

Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators. J Am Med Assoc 282 637-645... 

Kanis JA, Johnell O, Black DM, Downs RW Jr, Sarkar S, Fuerst T, et al. (2003) Effect of raloxifene on the risk of new vertebral fracture in postmenopausal women with osteopenia or osteoporosis a reanalysis of the Multiple Outcomes of Raloxifene Evaluation trial. Bone 33 293-300... 

Additionally it has been observed that raloxifene reduces the risk of breast cancer by 58-66%, without producing an increased risk of endometrial cancer in postmenopausal women (Cummings et al. 1999 Jordan et al. 1998). The Multiple Outcomes of Raloxifene Evaluation (MORE) clinical trial is particularly eloquent in this regard (Cummings et al. 1999). A total of7704 postmenopausal women (average age 66.5 years) with osteoporosis and without history of breast or endometrial cancer were included. The trial, which was randomized and double-blind, used two doses of raloxifene (60 or 120mg/d) or placebo to as-... 

---